Advance toward earlier detection of melanoma
Lihong Wang, Younan Xia, and colleagues point out that early diagnosis is key to improving survival in patients with melanoma. The five-year survival rate for melanoma is about 98 percent if detected early but can be as low as 15 percent when detected at an advanced stage. Existing imaging techniques for early detection of melanoma produce low-quality images, can "see" only a fraction of an inch below the skin, and use potentially harmful radioactive materials. A promising new technique called photoacoustic tomography (PAT) can overcome these problems. The system shoots light into tumors, which slightly heats up the cancer cells and produces high frequency sound waves that provide images of the tumor. But the PAT system lacks an optimal contrast agent that can easily enter skin cancer cells and make them visible.
The scientists developed such an agent by attaching a peptide (one of the building blocks of proteins) that targets skin cancer cells to gold "nanocages." These hollow gold nanoparticles have a box-like shape and are barely 1/50,000th the width of a human hair. When injected into mice with skin cancer, the nanocages improved the image quality of the cancer cells by three-fold compared to nanoparticles lacking the peptide. The gold nanocages also show promise as a way to kill skin cancer cells using heat or anti-cancer drugs, they add.
Topics
Organizations
Other news from the department science
These products might interest you
DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.